Introduction {#S1}
============

Drug addiction is a heterogeneous disorder characterized by cyclic periods of drug use, withdrawal and abstinence, and drug-craving and recurrence of use ([@B175]). Addiction is highly prevalent in our society, with an estimated 35 million people world-wide and 19.3 million people in the United States (US) currently meeting diagnostic criteria for a substance use disorder (SUD) ([Figure 1A](#F1){ref-type="fig"}; [@B334]; [@B346]). Additionally, epidemiological surveys suggest that, in a person's lifetime, there is a ∼10% prevalence of a SUD ([@B124]; [@B334]). Drug addiction is also one of the largest public health problems in the US, with an annual financial burden of \$740 billion in costs related to treatment, lost work productivity, healthcare, and crime ([@B237]). These numbers are likely to increase as illicit drug use is rising, with a quarter of a billion people worldwide reporting use in the past year ([@B346]). Within the US, over 17 million people aged 12 and above are estimated to initiate drug use annually. Rates of opioid use, in particular, are continuing to climb, with 53 million past-year opioid users worldwide and ∼11 million people in the US reporting opioid misuse within the past year ([@B346]). This is especially alarming, as the number of deaths in the US involving opioids has increased 6-fold from 1999 to 2017, with ∼130 Americans dying from use per day ([@B50]).

![Public health trends in drug use. **(A)** Drug use in the United States from 1990 to 2019. Data from the National Household Survey on Drug Abuse ([@B322]; [@B323]; [@B328]; [@B325]) and the National Survey on Drug Use and Health ([@B326]; [@B327]; [@B328]; [@B329]; [@B330]; [@B331]; [@B333]; [@B334]). **(B)** Unspecified polysubstance use in treatment-seeking drug users in Finland from 1997 to 2008. *Top*: Primary (left) and secondary (right) drugs used by treatment-seeking drug users, shown as percent of total users. *Bottom*: Percent of users reporting exclusive misuse of one drug (white bars) or misuse of a given drug along with polysubstance use of another (colored bars). Data from [@B249].](fnins-14-00569-g001){#F1}

Although the majority of research on SUDs has focused on individual substances in isolation, with a multiple drug use history often considered an exclusion criterion for clinical studies, it is important to recognize that many drug users engage in polysubstance use. For instance, 30--80% of heroin users have been reported to also use cocaine ([@B190]), and deaths involving both cocaine and opioids in the US more than doubled between 2010 and 2015 ([@B50]). A person is considered a polysubstance user if they use more than one substance, including use of multiple drugs on separate occasions (sequential use) or at the same time (concurrent/simultaneous). Limiting studies to individual drugs risks overlooking interactions between substances, decreases translatability of preclinical research, and can impede the efficacy of identified treatments for SUDs. Indeed, polysubstance use has consistently been associated with worse treatment outcomes, including poorer treatment retention, higher rates of relapse, and a three-fold higher mortality rate compared to mono-substance use ([@B369]; [@B314]; [@B78]). This review seeks to combine the current knowledge of the mechanisms and consequences of individual drug use with the most up-to-date research on polysubstance use, making sure to note, when possible, if polysubstance use is concurrent/simultaneous, sequential, or a combination of these patterns. We will first provide an overview of public health trends regarding single and polysubstance use, as well as the impact of polysubstance history on metrics of substance use severity. This will be followed by a discussion of findings from preclinical studies, and their translatability to real-world substance use, outlining considerations to be made when designing polysubstance studies. We then detail the pharmacology of individual substances and some of their effects on the cortical-basal ganglia-thalamic (C-BG-T) circuitry, which sets the groundwork for understanding how polysubstance use may change the neuropathology of addiction. Care will be given to discussing the differences between brain alterations in single versus polysubstance use, highlighting the most common combinations of polysubstance use. For clarity and in order to avoid duplication in our discussions, sections are organized by primary used substance, with consideration for the consequences that result when additional drugs are combined with a primary drug. Finally, we offer suggestions and highlight potential methods to move forward with the important task of examining polysubstance disorders.

Public Health Trends in Substance Use {#S2}
=====================================

Drug addiction is both pervasive and deadly, with ∼585,000 drug use-related deaths occurring each year worldwide ([@B346]). Nonetheless, although drug addiction and its impacts are often centered around individual drugs, drug misuse is largely found to involve multiple substances ([@B119]; [@B292]; [@B332]). Indeed, drug-dependent individuals report an average use of 3.5 substances ([@B249]), including both simultaneous and sequential polydrug use ([Figure 1B](#F1){ref-type="fig"}). In addition, the likelihood of developing comorbid substance dependencies is high in clinical populations ([@B193]; [@B204]). Although combinations of co-used substances vary, primary drug dependencies are typically found for alcohol, opioids, amphetamine, and methamphetamine, while cannabis and cocaine are more often reported as secondary-or tertiary-used substances ([@B332]). The high prevalence of polysubstance use is particularly concerning given the impact it can have on both SUD severity and treatment outcomes. For example, a polysubstance history is associated with greater unmet physical and mental health care needs, increased risk behavior, violence, and increased overdose and mortality risk compared to single substance use ([@B258]; [@B118]; [@B204]). In this section, we will discuss the public health consequences surrounding single substance use, as well as polysubstance use in relation to secondary substance combinations. This overview will aim to address overarching patterns of polydrug use, including the substance combinations and patterns of use that most commonly occur. However, given that data is limited for specific drug use patterns, types of classification, and differences in definition of polydrug combinations across studies, it is unlikely to capture all combinations, histories, and patterns of use.

Psychostimulants {#S2.SS1}
----------------

Psychostimulants are the second-most widely used class of drugs, with 18 million current cocaine users and 29 million current prescription stimulant users worldwide ([@B346]). Worldwide prevalence of psychostimulant use has remained relatively stable from 1990 to 2017, with 7.38 million reported to meet criteria for an amphetamine use disorder and 5.02 million reported to meet criteria for a cocaine use disorder ([@B84]). However, the number of drug-related overdose deaths involving psychostimulants has continued to climb, especially in the US, with a 2.6-fold increase in the cocaine overdose death rate and 3.6-fold increase in the methamphetamine overdose death rate from 2000 to 2017 ([@B84]).

Notably, cocaine and amphetamine users are predominantly polysubstance users, with one study reporting 74 and 80% incidence of polysubstance history, respectively ([@B165]). Specifically, cocaine use and developing a cocaine use disorder is associated with concurrent heroin, cannabis, tobacco, and alcohol use ([@B165]; [@B292]; [@B153]). Similarly, amphetamine users exhibit several types of polysubstance use, with high probabilities of alcohol, tobacco, and cannabis use. In addition, other classes of amphetamine polysubstance users exhibit higher probabilities of heroin and other opioid use. Across groups, lower probabilities of cocaine use with amphetamine compared to other drug classes used with amphetamine are reported as well ([@B75]; [@B168]). Polysubstance use is common among stimulant users with both concurrent and sequential drug consumption patterns. For instance, simultaneous use of psychostimulants and opioids is seen with both cocaine ("speedball") and methamphetamine ("bombita"). Sequential use of psychostimulants and opioids is also common, including the use of cocaine or amphetamine to avoid opioid-related somatic withdrawal symptoms ([@B145]; [@B93]) and the use of opioids to reduce overexcitation following cocaine use ([@B180]). Additionally, there is an increased likelihood of same-day methamphetamine use with alcohol consumption ([@B41]).

Though these studies did not specify the patterns of polydrug use, a meta-analysis of reports on concurrent versus simultaneous cocaine use found a 24--98% range of simultaneous cocaine and alcohol use and 12--76% incidence of simultaneous cannabis use ([@B200]). Rates of concurrent use were 37--96% for cocaine and alcohol use, 43--94% for cocaine and cannabis use ([@B200]), 70--80% for cocaine and nicotine use ([@B40]; [@B365]), and 85--95% for amphetamine and nicotine use ([@B32]; [@B126]). The high variability in reported frequencies highlights the complexity in identifying drug use patterns, which can vary across demographics, study periods, study structure, and definitions of concurrent and simultaneous use.

Polydrug use involving psychostimulants poses significant public health risks. For example, one study showed that amphetamine users were 21 times more likely to have a concurrent cannabis use disorder and 7 times more likely to have past-year concurrent cocaine use, compared to those with no prior history of amphetamine use ([@B214]). In addition, nearly one-third of overdose deaths involved both psychostimulants and opioids, such as heroin and fentanyl ([@B164]). The hazards of psychostimulant co-use also extend to other substances, with combined cocaine and cannabis use resulting in higher standardized death rates in emergency department (ED) visits, suggesting elevated mortality risks with this combination ([@B118]). Additionally, combining cocaine and alcohol use increases the risk for cardiotoxicity compared to either drug alone ([@B258]).

Nicotine {#S2.SS2}
--------

Although the use of tobacco (i.e. the dried leaves of the tobacco plant containing nicotine) has declined since the early 2000s, nicotine is still one of the most commonly used drugs, with 58.8 million people aged 12 or above reporting past-month nicotine use in the US ([@B334]). It is also commonly used with many other substances, as 17% of nicotine users also used cannabis, 4.7% also used opioids, 2.6% also used cocaine, and 1.4% also used psychostimulants in the past month. In contrast, nonsmokers had much lower percentages of past-month substance use (3.7, 1.2, 0.2, and 0.3% for the aforementioned substances, respectively), ([@B226]). This difference is notable, given that people with a nicotine use disorder are 3--4 times more likely to have a second SUD ([@B57]). In addition, it was found that past-year tobacco use was significantly associated with opioid use disorders, as well as comorbidities for cannabis and alcohol use and use disorders, and cocaine use in samples of primary care patients ([@B154]). Tobacco use severity (i.e. frequency of use and number of cigarettes smoked) has also been significantly correlated with onset of heroin and cocaine use ([@B110]). Historically, nicotine has primaryily been used by smoking tobacco cigarettes. However, new advances in technology have led to the development of electronic (e-) cigarettes, designed to deliver nicotine in a toxin-free manner. The marketing of e-cigarettes as a safer alternative to traditional tobacco cigarettes is concerning, as it has led to an increase in the probability of nicotine use and a resurgence in the potential for nicotine addiction. For example, e-cigarette use among middle and high school students has increased from 2012 to 2016 ([@B115]), and a spike in use was observed among young adults (18--24 years old) around 2013 to 2014, when e-cigarette products were introduced ([@B115]). Despite delivery of lower doses of nicotine, the safety of commercial e-cigarettes has been debated, since compensatory "puffing" behaviors or high voltage settings leads to the production of carcinogenic agents ([@B152]). The potential danger of use is further compounded by the variable amounts of nicotine provided across e-cigarette manufacturers ([@B121]). The unique influence of vaping on the development of nicotine dependence and how this differentially contributes to polysubstance use disorders remains largely unknown and should be studied in the coming years.

Opioids {#S2.SS3}
-------

The prevalence of opioid misuse (i.e. use outside of prescribed use) has risen dramatically in recent years, with ∼53 million adults (1.1% of global population) reporting past-year non-medical use of an opioid ([@B346]). In the US alone, 11 million people reported past-year opioid misuse in 2016 ([@B333]); however, this estimate is conservative as it does not include homeless or incarcerated individuals with disproportionately higher levels of opioid use. In addition, the rate of first-time heroin users rose in parallel with non-medical use of prescription opioids from 2002 to 2011 ([@B346]), a reflection that suggests individuals with past-year prescription opioid misuse are 19 times more likely to initiate heroin use than those without such a history ([@B234]; [@B59]). Studies have investigated polydrug use among heroin and prescription opioid misusers and found higher frequencies of opioid use in people that also use cocaine (\>33%) or methamphetamine (\>20%) ([@B363]; [@B135]), but reduced prevelance for primary opioid use in those that have secondary alcohol or cannabis use ([@B363]; but see [@B58]). In addition, first-time methamphetamine use is more prevalent following past-month opioid use ([@B58]). Of those entering treatment for heroin use, it has been found that 91% of people reported a lifetime history of cocaine use ([@B369]). Additionally, a study in the United Kingdom found that 54% of opioid users in treatment between 2017 and 2018 also had a comorbid crack cocaine use disorder ([@B277]). With respect to patterns of multi-drug use, simultaneous use of heroin with alcohol and/or cannabis is more common than with psychostimulants ([@B168]; [@B26]), and a sequential pattern of drug use is preferred for opioids and psychostimulants.

In the US, opioid use is a national public health emergency responsible for more than 1.6 million years of life lost from 2001 to 2016 ([@B120]). Moreover, opioid overdose deaths are currently the leading cause of accidental death among US adults, with 68% of all drug overdose deaths involving an opioid ([@B346]). Given that nearly 80% of fatal opioid overdoses also involved another substance, it appears that there is a greater risk of death when opioids are used in combination with other opioids and/or other drugs ([@B157]). Specifically, of these deaths, 78% involved another opioid, 21.6% involved cocaine, 11.1% involved alcohol, and 5.4% involved a psychostimulant other than cocaine ([@B157]). Furthermore, opioid-related ED visits also involved tobacco (51.1%), cocaine (36.9%), other stimulants (22.6%), cannabis (25.1%), or alcohol (16.9%). Substantial polysubstance use of three or more of these substances has also been reported for opioid-related ED visits ([@B199]), and the likelihood of these visits has been associated with the degree of severity of other SUDs ([@B377]; [@B154]). Taken together, these reports suggest that combining opioid use with use of other substances can exacerbate the deleterious consequences of opioid use. In addition to overdose risk, opioid users experience very high rates of relapse, with 59% of individuals relapsing in the first week and 80% relapsing in the first month of abstinence ([@B307]). Past use of other substances, including the degree of cocaine use, increases relapse susceptibility ([@B369]). Methamphetamine use among those seeking treatment for opioid use has also been on the rise ([@B346]), and recent reports indicate that methamphetamine use is associated with a discontinuation of buprenorphine treatment in people with an opioid use disorder ([@B345]). Thus, a better understanding of the impact of polysubstance use in the context of opioids is crucial for more successful emergency responses and long-term treatment outcomes.

Cannabinoids {#S2.SS4}
------------

It is estimated that 188 million individuals 12 years or older use cannabis worldwide ([@B346]), including 43.5 million individuals in the US ([@B334]). Beginning in 2012 with Washington and Colorado, 11 states and the District of Columbia have legalized recreational cannabis, making it legally accessible to ∼328 million people. The number of cannabis users in the US has risen with its gradual decriminalization and legalization, from 4.1% in 2002, to 9.9% in 2007, to 15.9% in 2018 ([@B132]; [@B334]). Frequency of cannabis use is also high, with reports of 40% of individuals being daily or near-daily users ([@B334]).

Cannabis users are reported to have high rates of past month tobacco, alcohol, and/or amphetamine use ([@B63]). One of the most common combinations is simultaneous use of alcohol and cannabis ([@B216]), along with simultaneous alcohol, cocaine, and cannabis use ([@B200]). The impact of concurrent cannabis is notable, as this pattern of use is associated with more alcoholic drinks per day, suggesting facilitation of alcohol use with coexisting cannabis consumption ([@B2]; [@B321]). Polydrug use is particularly prevalent in younger populations. Among adolescent cannabis users, 27.5% reported additional drug use within the same year of starting cannabis use, and nearly 67% use two or more other drugs ([@B320]). Cannabis is frequently used during treatment for other SUDs ([@B63]; [@B321]), and this has been associated with reduced treatment efficacy. For example, cannabis use has been found to result in shorter periods of alcohol abstinence ([@B321]), as well as greater incidence of relapse to cocaine ([@B2]; [@B227]). In addition, polydrug use among cannabis users has been correlated with reduced socioeconomic mobility, financial instability, and relationship difficulties ([@B2]; [@B51]; [@B321]), a heightened degree of mood disorder symptom severity, decision-making deficits, social difficulties, and self-harm ([@B320]; [@B203]). Although these data suggest that the consequences of drug use are enhanced by concurrent cannabis use, it should be noted that clinical outcomes can vary for studies examining polydrug use among cannabis users. For example, some studies suggest a nuanced impact of polysubstance use that is dose-dependent, with no synergistic effects of cannabis and alcohol at low doses of either drug ([@B10]), and a lack of association of cannabis use in heroin relapse ([@B2]).

Alcohol {#S2.SS5}
-------

Alcohol is one of the most commonly used drugs, with up to 290 million people diagnosed with an alcohol use disorder worldwide ([@B346]), including 15 million people in the US ([@B334]). Alcohol is frequently used with other substances, with reports indicating that 5.6% of US adults have used both alcohol and another illicit drug within the past year, and 1.1% have met diagnostic criteria for both an alcohol use disorder and another SUD ([@B98]). The most commonly reported substance co-used with alcohol is cannabis (10%), with less common comorbidities found with opioids (2.4%), cocaine (2.5%), and amphetamine (1.2%) ([@B98]). Although simultaneous use of alcohol and cannabis or alcohol and prescription opioids is most common ([@B216]), simultaneous use is also seen with cocaine ([@B200]).

Polydrug use increases the risk of developing an alcohol use disorder ([@B123], [@B124]), particularly in young adults, men, and American Indians/Alaskan Natives ([@B98]). Polydrug use that includes alcohol is associated with additional comorbidities, including higher prevalence of mood disorders, anxiety disorders, more intense drinking, and more intense drug consumption and drug-craving ([@B276]; [@B296]). The negative consequences of alcohol polydrug use are also highlighted by data indicating that 21% of ED visits for patients 12--24 years old involved both alcohol and drugs. These visits were also more likely to require treatment for injuries, and had higher rates of inpatient admittance ([@B235]). In addition, 17% of substance treatment admissions were related to both alcohol and drug use, representing 45% of primary alcohol admissions and 33% of drug misuse admissions ([@B368]; [@B332]; [@B235]). The rate of hospitalizations involving alcohol polydrug use has been increasing, particularly in young adults, with reports suggesting a 76% rise in inpatient admittance between 1998 and 2008, compared to either drug or alcohol overdoses alone ([@B368]). While the polysubstance users in these surveys were primarily white and male, recent trends indicate a rise in ED visits relating to alcohol and drug combinations in females ([@B235]), suggesting a change in the demographics of polysubstance combinations that include alcohol.

Behavioral Models of Addiction in Polydrug Studies {#S3}
==================================================

Behavioral models of drug addiction are used to examine the neurobiological underpinnings of the development, maintenance and relapse to drug use. The most commonly used models are locomotor sensitization (a progressive and persistent increase in locomotor responses to the same dose of a drug), conditioned place preference (CPP; a test of drug reward measured as an increase in time spent in a drug-paired chamber) and drug self-administration (response-contingent intake of drug) (see [@B251]; [@B310]; [@B184] for review). Experimental designs using these models vary across a number of pharmacological and non-pharmacological parameters including contingency of drug use, amount of access to drug, context associated with drug use, and routes of administration. Here, we describe how these models have been used with polydrug combinations, and how this work has informed our understanding of polydrug use and addiction.

Initial polysubstance studies largely used noncontingent models of drug administration, particularly CPP and cross-sensitization models, whereby the impact of priming doses of one drug on side preference or motor activity, respectively, of another drug are determined ([@B305]; [@B205]; [@B62]; [@B191]; [@B196]). More recently, studies have been examining how drug self-administration history impacts subsequent drug choice preference and/or drug-craving via responding to drug-associated cues following extinction and/or withdrawal ([@B192]; [@B79]; [@B293]; [@B70]). Preclinical polysubstance models involving simultaneous administration of multiple drugs, such as alcohol and nicotine or cocaine and heroin combinations, have also been used frequently ([@B225]; [@B221]; [@B303]). In clinical models, both concurrent and sequential polysubstance use is assessed in subjects via scoring of affective measures to drug-taking, drug-craving following visual cues, and autonomic response measures such as blood pressure and heart rate ([@B102]; [@B128]; [@B117]).

More recently, studies are comparing single versus polysubstance self-administration to determine the effect of drug history on drug-induced molecular and circuit alterations ([@B34]; [@B317]; [@B381]). Additionally, paradigms based on behavioral economic principles can determine the preferred level of drug intake (i.e. no-cost intake; Q~0~), as well as the amount of effort an animal is willing to exert to defend Q0 before consumption and responding begins to decline (i.e. price; P~max~) ([@B245]). These paradigms are especially powerful in that they can use Q~0~ and P~max~ to generate normalized measures of value (i.e. essential value; α) and price (~n~P~max~), which have been used to compare price sensitivity, effort, and value across different drug and non-drug rewards in polysubstance models in several species (e.g. in rats, rhesus monkeys, and human participants) ([@B263]; [@B364]; [@B361], [@B360]; [@B70]). In particular, these studies permit examination of the relative reinforcing properties of different doses and classes of drugs ([@B361]; [@B64]; [@B146]), as well as alterations in cost valuation for a drug following pre-exposure to another drug ([@B64]; [@B142]; [@B231]). Direct quantification of the assigned value of these drugs across different polysubstance histories and drug doses is very useful for assessing the impact of polysubstance history on relative reinforcer value. Furthermore, these measures can be used to compare how polysubstance users value drug rewards across different experimental parameters (e.g. differences in priming dose of one drug, environmental context, pattern of drug use). Finally, clinical studies are using questionnaires or controlled laboratory environments to investigate the behavioral effects of a polysubstance history. Specifically, these studies use monetary choice procedures that compare assigned value of drugs at different doses ([@B128]), how assigned value changes for one drug with a change in price of another ([@B263]; [@B262]; [@B335]; [@B52]), or how relative value of one drug changes with perceived change in subjective quality of another available drug ([@B61]). Additionally, progressive ratio tests for a single drug or drug combinations to study motivation ([@B128]), and delay-discounting rates for money and drug rewards to study decision-making, ([@B319]) have also been performed. These studies permit comparison of perceived value across multiple drugs in participants with histories of single or polysubstance use (for further review, see [@B137]).

Effects of Polydrug Use on Addictive Behaviors {#S3.SS1}
----------------------------------------------

Given the unique neurobiological alterations that can occur with exposure to multiple drugs, along with the high prevalence of polysubstance use disorders, there is a strong need to develop polydrug paradigms that have high translational value. These paradigms are critical for fully understanding the behavioral changes and addiction-related phenotypes that develop following polydrug use. However, given the vast number of potential substance combinations and the variability in methodologies that exist across studies, there are currently mixed results and interpretations regarding the impact of polydrug history on addiction-related behaviors. Nonetheless, some general trends in drug consumption, drug preference and drug-seeking have been demonstrated in commonly investigated substance combinations ([Figure 2](#F2){ref-type="fig"}).

![Summary of the effects of specific polydrug combinations on assays of addiction-like behaviors. Studies are organized into X/Y polydrug combos (columns) and behavioral assays (rows), with subcolumns for the effect of drug Y on drug X (left subcolumn) and the effect of drug X on drug Y (right subcolumn). Symbols represent the net effect of the X/Y polydrug combo on a given behavior, with color depicting the specific drugs tested. Sensitization: locomotor sensitization; Conditioned place preference: acquisition, expression; Drug intake: self-administration; Motivation: progressive ratio, behavioral economics; Drug craving: reinstatement, cue reactivity. Data from [@B223], [@B224], [@B222], [@B147], [@B102], [@B6], [@B282], [@B349]; [@B82], [@B255]; [@B309], [@B196]; [@B20], [@B364]; [@B253], [@B254], [@B370], [@B188], [@B187], [@B194], [@B66], [@B272], [@B208]; [@B209], [@B104]; [@B117], [@B129]; [@B301], [@B371]; [@B211], [@B275], [@B70], and [@B317].](fnins-14-00569-g002){#F2}

### Psychostimulants {#S3.SS1.SSS1}

Some of the more commonly studied polydrug combinations include administration of cocaine with other drugs ([@B103]; [@B191]; [@B332]). However, in contrast to human reports ([@B136]; [@B369]; [@B314]; [@B276]; [@B204]; [@B164]), an increase in addiction-like severity has not been observed in preclinical studies, suggesting a need for models with greater translational relevance that can capture the enhanced severity seen in human polysubstance users. Specifically, animal studies of sequential cocaine and alcohol or cocaine and heroin use have not found differences in drug intake or reinstatement of drug-seeking as a function of single versus polydrug use ([@B257]; [@B104]; [@B70]; [@B317]). These effects were observed despite variance in the use of contingent and non-contingent drug administration, drug doses, and species, including rats ([@B70]; [@B317]) and rhesus monkeys ([@B6]). Consistent with this work, intermittent alcohol exposure has not been shown to affect cocaine self-administration ([@B6]; [@B104]) or the reinforcing properties of cocaine measured via demand curves in rhesus monkeys ([@B370]). In addition, intermittent alcohol exposure has not been shown to affect progressive ratio tests of motivation for cocaine ([@B215]), or the long-term reconsolidation of preference for cocaine in drug-paired contexts ([@B381]) in rats. In contrast, adolescent alcohol exposure has been shown to have long-lasting effects on cocaine self-administration and reward, suggesting that this population is particularly susceptible to the effects of polysubstance use. For example, adolescent alcohol exposure increases motivation for cocaine ([@B215]), enhances the development of a cocaine CPP in both mice ([@B228]) and rats ([@B148]; [@B215]), and weakens cocaine-induced taste aversion ([@B44]). In addition, simultaneous heroin and psychostimulant administration increases the motivation to self-administer cocaine ([@B364]) and methamphetamine ([@B282]), and both simultaneous and sequential administration of morphine and methamphetamine have been shown to be rewarding, as measured by the development of a CPP ([@B34]). Pretreatment with an opioid also enhances methamphetamine-induced psychomotor sensitization ([@B196]). These findings suggest that opioids can enhance the rewarding and motivational properties of psychostimulants, particularly when administered simultaneously.

Polydrug studies with cocaine and nicotine have largely reported additive and/or synergistic effects of the two drugs. In particular, co-administration of cocaine and nicotine increases drug intake in rhesus monkeys ([@B222]) and rats ([@B13]), enhances locomotor sensitization and the development of a CPP in mice ([@B194]), and induces a cross-sensitized drug-craving ([@B284]; [@B365]; [@B67]). Additionally, chronic nicotine pretreatment facilitates the acquisition of cocaine self-administration ([@B143]; [@B13]; [@B198]), increases motivation under a progressive ratio schedule, impairs extinction learning, and enhances drug-primed reinstatement for amphetamine following amphetamine self-administration ([@B67]). Conversely, prior nicotine treatment history reduces demand elasticity for cocaine ([@B301]). Notably, the effects of nicotine and psychostimulant polydrug use are largely dose-dependent as pretreatment with a smaller dose of nicotine \[0.3 mg/kg, subcutaneous (*sc*)\] increases motivation to take cocaine under a progressive ratio schedule in rats, whereas a larger dose of nicotine (0.6 mg/kg, *sc*) has the opposite effect ([@B13]). Additionally, simultaneous administration of methamphetamine \[2.0 mg/kg, intraperitoneal (*ip*)\] and nicotine (1.0 mg/kg *ip*) induces a conditioned place aversion in mice, while sequential administration of the same dose induces a CPP ([@B34]). Together, these studies demonstrate that the effects of nicotine on psychostimulant motivation, intake, and reward are heavily impacted by the parameters surrounding nicotine delivery (e.g. dose, route, pattern, etc.), which should be carefully considered when comparing study results and developing preclinical polydrug paradigms. Notably, adolescent exposure to nicotine has no effect on the subsequent development of a cocaine CPP, cocaine-induced taste aversion, cocaine self-administration, extinction, or reinstatement of cocaine-seeking in adulthood ([@B272]), although it has been shown to enhance cocaine self-administration in adolescent rats ([@B198]). These data suggest that, unlike alcohol, early exposure to nicotine does not lead to increases in addiction-like behavior to cocaine in animals.

In humans, simultaneous cocaine and cannabis use produces feelings of "stimulated" and "high" that last longer than either drug alone ([@B102]), and cue-induced drug-craving in individuals who co-use cocaine and cannabis lasts longer than for those who only use cocaine ([@B117]). In contrast, THC reduces the motivation to self-administer cocaine in rodents ([@B253]). Although this suggests a differential regulation of cocaine's effects in humans and rodents, further work is necessary to ensure that animal models of increased addiction severity cannot, in fact, be developed. Notably, however, neither cocaine and cannabis nor cocaine and alcohol co-administration in humans produces subjective effects that are different from cocaine, cannabis, or alcohol alone ([@B102]). Similarly, THC pretreatment in rodents has no effect on psychostimulant reward or self-administration, nor does it potentiate the development of a CPP to amphetamine ([@B253]; [@B66]; [@B166]), indicating a unique effect of cocaine and cannabis on drug-craving. Interestingly, CBD has no effect on cocaine self-administration, motivation, or cue-induced reinstatement of cocaine-seeking ([@B209]), suggesting the effects of cannabis on cocaine craving are likely due to THC, rather than CBD. However, CBD treatment has been found to reduce motivation to self-administer methamphetamine on a progressive ratio schedule and to reduce methamphetamine-primed reinstatement of drug-seeking ([@B133]). The additive effects of cannabinoid and psychostimulant polydrug use appear to be dependent on both the amount of drug consumed and the age range during use. For example, acute THC weakens psychomotor sensitization, but repeated THC administration promotes tolerance to the acute effects, increasing amphetamine-induced stereotypy and locomotor activity ([@B122]; [@B66]). Additionally, adolescent THC exposure accelerates acquisition of cocaine self-administration and increases intake of low doses of cocaine ([@B107]), indicating long-lasting changes in reward circuitry following adolescent THC use, similar to alcohol.

### Nicotine {#S3.SS1.SSS2}

Limited work has focused on the effects of polydrug use on nicotine-induced addiction behaviors. However, it has been found that THC pretreatment can enhance nicotine consumption and price inelasticity (measured by α) in behavioral economic tests in rats ([@B254]), and heroin intake has been found to increase cigarette consumption in people ([@B224]). In addition, pre-exposure to alcohol or simultaneous access to both alcohol and nicotine decreases nicotine self-administration in rodent studies ([@B188], [@B187]). Although access to alcohol has no effect on responding for nicotine under extinction conditions, a priming dose of alcohol does reinstate nicotine-seeking ([@B188]). Finally, systemic co-administration of methamphetamine and nicotine produces a conditioned place aversion in rats ([@B34]), whereas pretreatment with either amphetamine or morphine increases the rewarding properties of nicotine as shown with lowered intracranial self-stimulation thresholds ([@B147]). These studies further emphasize the need to consider use patterns and dose in interpretation of polydrug use effects.

### Opioids {#S3.SS1.SSS3}

Similar to psychostimulant polydrug studies, sequential use of heroin and cocaine has not been found to alter heroin self-administration or reinstatement of heroin-seeking ([@B70]). Although alcohol pretreatment can prevent the long-term reconsolidation of preference for morphine in drug-paired contexts ([@B381]), adolescent alcohol exposure enhances the development of a morphine CPP ([@B228]). This finding indicates that the long-term effects of adolescent alcohol exposure are generalizable to multiple drug classes. Interestingly, co-administration of morphine and THC prevents the development of the analgesic tolerance that normally accompanies long-term exposure to either drug alone ([@B60]; [@B68]; [@B306]). In addition, the analgesic effects of THC and oxycodone co-administration are additive to oxycodone alone ([@B241]). Moreover, administration of either THC or both THC and CBD attenuates naloxone-precipitated withdrawal without impacting the development of a morphine CPP ([@B197]; [@B349]). These data suggest a potential role for cannabinoids in regulating a physical dependence to opioids without altering their reinforcing properties. In support of this, repeated THC administration has no effect on breakpoint during a PR test of heroin self-administration ([@B308], but see [@B241]) or relapse to heroin-seeking, although it produces a small reduction in both heroin ([@B208]) and oxycodone ([@B241]) intake in fixed-ratio self-administration sessions. The effects of opioid and cannabis polydrug use, however, appear to be dose-dependent as systemic administration of THC prior to heroin self-administration reduces responding for large doses of heroin, but has no effect on responding for lower doses in both monkeys and rats ([@B308]; [@B208]).

### Cannabinoids {#S3.SS1.SSS4}

As with psychostimulants and opioids, administration of nicotine with THC augments the effects of either drug alone when measured in tests of locomotion, analgesia, and hypothermia ([@B348]). In addition, THC and nicotine co-administration exacerbates the somatic symptoms of THC withdrawal ([@B348]). However, after repeated nicotine treatment and 2 weeks of drug abstinence, nicotine re-administration attenuates THC-induced decreases in locomotor activity, increases in anxiety measures (when assessed in the elevated-plus maze), and changes in social interaction ([@B211]). These findings suggest that nicotine enhances the negative symptoms of THC when administered concurrently or in close temporal proximity. Although nicotine pretreatment enhances the rewarding effects of subthreshold doses of THC ([@B275]), cocaine pretreatment heightens THC-induced anxiogenic behaviors ([@B253]). Cannabis and alcohol polydrug use is relatively common in humans, and individuals report reduced alcohol consumption when cannabis is available ([@B223]), suggesting a role for cannabinoids in alcohol intake. However, drug-induced cognitive and physical impairments in humans, as assessed in a driving simulation, were found to be more severe after use of THC and alcohol compared to either drug alone ([@B90]). Conducting polydrug studies of combinations of THC or CBD with other drug classes is therefore necessary to understand the differential effects resulting from these drugs.

Unfortunately, due to long-term restrictions on cannabis research in the US and past difficulties in modeling cannabis use with self-administration models in rodents ([@B252]), much less is known about the impact of cannabis relative to other drugs. The development of novel methods of cannabis self-administration in animals, including oral self-administration of Δ9-tetrahydrocannabinol (THC)-containing gelatin ([@B182]), self-administration of vaporized THC and cannabidiol (CBD) ([@B105]), and intravenous self-administration of THC and CBD ([@B239]) will help facilitate the preclinical study of cannabis use disorder, as well as enable us to better understand the consequences of polydrug use involving cannabis.

### Alcohol {#S3.SS1.SSS5}

Polydrug use of alcohol and nicotine produce mixed phenotypes in relation to addiction behaviors. For example, pre-exposure to alcohol or simultaneous access to both alcohol and nicotine increases alcohol self-administration, but not when nicotine is administered prior to alcohol each day ([@B188], [@B187]). Chronic nicotine treatment also enhances alcohol preference, an effect that persists through nicotine withdrawal ([@B24]). However, although access to nicotine impairs extinction learning to alcohol responding, it has no effect on reinstatement of drug-seeking, as rats respond similarly on alcohol and nicotine-associated levers following a priming injection of nicotine ([@B188]). Nonetheless, another study found that priming doses of alcohol, but not nicotine, were capable of reinstating alcohol-seeking following self-administration of both nicotine and alcohol ([@B303]). Studies have not systematically examined the effects of other drugs on alcohol use and addiction.

Neurobiology of Addiction {#S4}
=========================

The development and maintenance of addiction behaviors arises in part from maladaptive neuroplasticity within the neural circuits responsible for decision-making, learning, motivation, and reward processing. In particular, alterations in the cortico-basal ganglia-thalamic (C-BG-T) network are known to contribute to drug-taking and drug-seeking behaviors, as well as the persistence of SUDs ([@B175]). The C-BG-T is a heavily interconnected network that integrates sensory and interoceptive cues to drive motivated behavioral output. The striatum, which serves as an interface of the C-BG-T, receives extensive glutamatergic input from cortical (e.g. prefrontal) and subcortical (e.g. amygdala, hippocampus, thalamus) regions, along with dopaminergic input from the midbrain \[substantia nigra (SN)/ventral tegmental area (VTA)\] ([@B116]; [@B46]). Integration of glutamatergic and dopaminergic inputs with local inhibition in the striatum contributes to the initiation or suppression of behavioral output, and imbalanced signaling between the two striatal output pathways (i.e. the direct and indirect) can drive addictive behaviors ([@B178]; [@B100]; [@B248]). It is beyond the scope of the current review to fully explore all of the neurobiological changes that occur in the C-BG-T with drug use. We will instead focus on one microcircuit within the C-BG-T that is central to the acute effects of drugs with addictive potential, and in some of the persistent changes that develop following long-term drug use: The prefrontal cortex (PFC) -- nucleus accumbens (NAc) -- VTA network ([Figure 3](#F3){ref-type="fig"}). Following a review of the microcircuitry and connectivity of these regions, we will discuss disruptions that occur within this network following both acute and long-term exposure to different classes of drugs, with emphasis on the similarities and/or differences of effects relative to polydrug combinations.

![Neural circuitry targeted by potentially addictive drugs. Simplified schematic emphasizing local and distal connections between the PFC, NAc, and VTA that are targeted by potentially addictive drugs. *Left*: NAc^MSNs^ receive excitatory glutamatergic inputs from PFC^GLU^ neurons, dopaminergic inputs from VTA^DA^ neurons, and inhibitory GABAergic inputs from other NAc^MSNs^. *Right*: VTA^DA^ neurons are maintained under tonic inhibition by local VTA^GABA^ interneurons and NAc^MSNs^ and receive excitatory inputs from PFC^GLU^ neurons. DA: dopamine; GLU: glutamate; MSN: medium spiny neuron; NAc: nucleus accumbens; PFC: prefrontal cortex; VTA: ventral tegmental area.](fnins-14-00569-g003){#F3}

Prefrontal Cortex {#S4.SS1}
-----------------

The PFC is centrally involved in reward learning, decision-making, and outcome valuation ([@B114]). It is a highly heterogenous structure, which adds to the complexity in understanding its role in cognition, as well as how its dysregulation contributes to drug use and addiction. In general, the medial prefrontal cortex (mPFC) -- encompassing the anterior cingulate (ACC), prelimbic (PrL), and infralimbic (IL) cortices -- regulates motivation and seeking of both natural and drug rewards via excitatory glutamatergic projections to the NAc and VTA ([@B175]). Notably, projections from the mPFC to the NAc are topographically organized, with the PrL innervating the NAc core and the IL innervating the NAc shell ([@B36]). In contrast, the orbitofrontal cortex projects more heavily to the dorsal striatum and SN and is primarily involved in outcome and probability valuation ([@B250]). Hypoactivity in the PFC contributes to drug craving and seeking despite negative consequences in preoccupation stages of addiction, with dysregulated connectivity to the striatum and VTA contributing to cue sensitivity and motivated drug-taking ([@B357]). The PFC is comprised of six layers, each with unique connectivity patterns and distinct cell types. Specifically, a majority of PFC neurons are large pyramidal output cells (75%), as well as several subtypes of interneurons (∼25%) ([@B298]). Pyramidal cells in layers II/III send local projections within cortex, while those in layers V-VI send projections throughout the C-BG-T, including to the striatum, midbrain, amygdala, hippocampus, and thalamus ([@B112]; [@B298]). Pyramidal cells can be further subdivided based on physiology and connectivity ([@B230]; [@B39]; [@B285]; [@B318]; [@B169]). Recent studies have begun to characterize the anatomical, electrophysiological, and molecular profiles of each of these cell types ([@B161]; [@B169]; [@B297]; [@B56]; [@B372]), though how they each regulate behavior remains poorly understood. Finally, the PFC contains multiple populations of interneurons that heavily regulate cortical output via projections to both pyramidal neurons and interneurons ([@B352]; [@B12]).

Nucleus Accumbens {#S4.SS2}
-----------------

The striatum is a heterogeneous structure comprised primarily of two interspersed populations of GABAergic medium spiny neurons (MSNs) that can bidirectionally regulate behavioral output. Direct pathway MSNs (dMSNs) express dopamine D1-like (D~1~) receptors and the neuropeptides dynorphin and substance P, project directly to the midbrain, and can promote behavioral output by serving as a "go" signal. Conversely, indirect pathway MSNs (iMSNs) express dopamine D2-like (D~2~) receptors and the neuropeptide enkephalin, project indirectly to the midbrain via the pallidum (GPe and VP), and can suppress behavioral actions by serving as a "stop" signal ([@B178]; [@B116]). Drug use promotes increased phasic dopamine from D~1~ activation, prompting reward attribution to drug use during binge/intoxication phases of the addiction cycle, conditioning, and incentive salience attribution to drug-taking contexts ([@B359]; [@B175]). The striatum contains dorsal and ventral compartments, with further subdivisions based on connectivity and function. The ventral striatum -- comprised of the olfactory tubercule, NAc core, and NAc shell -- receives dopaminergic modulation from the VTA and glutamatergic input from the PFC, as well as thalamic, hippocampal, and amygdala nuclei ([@B195]). In general, the ventral striatum regulates motivated behavior and reward learning. However, it has been hypothesized that an ascending loop between the ventral and the dorsal striatum facilitates information consolidation during learning, whereby habitual behaviors transition from the ventral striatum to the dorsal striatum, contributing to compulsive drug-seeking ([@B89]; [@B175]; [@B43]). Importantly, while dMSNs and iMSNs have historically been differentiated by downstream targets and expression of dopamine receptors, ventral striatal dMSNs send collaterals to the VP ([@B49]; [@B185]), and D~1~ and D~2~ receptors are co-expressed to some degree in the NAc core (6--7%), and NAc shell (12--15%) ([@B19]; [@B113]). In addition to MSNs, the striatum contains large, tonically active cholinergic interneurons and multiple subtypes of GABAergic interneurons with distinct electrophysiological properties and peptide expression patterns ([@B43]). MSNs also receive cholinergic modulation from other projections ([@B76]), though the relevance of these inputs to local or network dynamics and the role of cholinergic striatal neurons in the addiction cycle remains uncertain. Interestingly, each MSN receives ∼5000--15000 excitatory inputs in addition to ∼1200--1800 GABAergic inputs from other MSNs, therefore, modulation of MSN activity via cholinergic and dopaminergic inputs appears necessary for signal integration and effective synaptic plasticity ([@B233]; [@B43]). Indeed, MSNs exhibit bi-stability, residing almost exclusively in either a down-state (−80 mV) or an up-state (−50 mV, near threshold) in the absence of external input. In addition, the maintenance of bi-stability and intrinsic excitability relies on the activity of cation channels that are under robust dopaminergic and cholinergic modulation ([@B271]; [@B233]). Maintenance of intrinsic excitability within MSNs is critical for normal regulation of behavioral output, and dysregulation of striatal microcircuitry contributes to the development and expression of addiction behaviors ([@B27]; [@B315]; [@B248]).

Ventral Tegmental Area {#S4.SS3}
----------------------

The VTA sends dopaminergic projections to cortical, striatal, and subcortical (e.g. hippocampus, amygdala, thalamus) areas to modulate C-BG-T network activity ([@B174]). Dopaminergic projections from the VTA to the NAc regulate goal-directed behaviors and have been heavily implicated in the binge/intoxication phase of SUDs ([@B175]). Recently identified subtypes of VTA^DA^ neurons with unique molecular profiles preferentially project to the NAc core or NAc shell, and regulate reward learning or motivation, respectively. However, co-activation of both populations appears to be necessary for robust reinforcement ([@B140]). VTA^DA^ neurons receive dense glutamatergic input from the PFC and several midbrain structures, as well as GABAergic input from a variety of sources (reviewed in [@B229]), including the NAc and local VTA^GABA^ neurons. VTA^GABA^ neurons maintain tonic DA levels via inhibition of VTA^DA^ neurons, and brief disinhibition of VTA^DA^ neurons results in phasic DA release into the NAc. VTA^GABA^ neurons receive glutamatergic input from the PFC and a number of subcortical nuclei, as well as GABAergic input from throughout the brain, including the NAc ([@B229]). The VTA also contains glutamatergic neurons that project to striatal interneurons ([@B37]; [@B280]), though the inputs to and behavioral relevance of these neurons is unknown. Notably, the VTA contains subpopulations of DA neurons that can release glutamate and/or GABA ([@B170]; [@B18]; [@B229]), allowing the VTA to modulate local C-BG-T activity at multiple levels and time scales. Within the NAc, the activity of VTA^DA^ neurons is modulated by dopamine D~2~ autoreceptors on VTA^DA^ terminals and cholinergic interneurons ([@B229]).

Mechanisms of Addiction: Acute Drug Effects {#S4.SS4}
-------------------------------------------

A unique feature of all potentially addictive drugs is the ability to reinforce the binge/intoxication phase of the addiction cycle via evoked phasic DA release into the NAc, yet the underlying mechanisms vary across drugs ([Figure 4](#F4){ref-type="fig"}; [@B357]). Psychostimulants disrupt DA reuptake into VTA^DA^ terminals ([@B273]), nicotine and alcohol directly activate VTA^DA^ neurons ([@B267]; [@B35]), and opioids and cannabinoids disinhibit VTA^DA^ neurons ([@B267]; [@B54]). The synergistic and antagonistic interactions between different drugs within the C-BG-T lends complexity to the study of polydrug use, and little is known about the mechanisms underlying the acute effects of specific polydrug combinations. However, *in vivo* extracellular recordings in rats that alternatively self-administered cocaine and heroin in the same session found that only ∼20% of PFC and NAc neurons responded similarly to both drugs ([@B53]), indicating divergent engagement of the C-BG-T by these drugs. Thus, examining the synergistic and antagonistic mechanisms of different drugs can guide our understanding of how specific polydrug combinations may disrupt C-BG-T network dynamics and contribute to the manifestation of addiction behaviors.

![Primary mechanisms of action of potentially addictive drugs. Potentially addictive drugs increase DA release into the NAc, but different drugs act via distinct mechanisms. *Top*: Opioids and cannabinoids disinhibit VTA^DA^ neurons via presynaptic inhibition of VTA^GABA^ and NAc^MSN^ inputs through four notable mechanisms: Inhibition of VG Ca^2+^ channels, activation of GIRKs, inactivation of AC, and inhibition of GABA release. Nicotine activates VTA^DA^ neurons via direct activation of somatodendritic nAChRs and activation of presynaptic PFC^GLU^ inputs. Alcohol directly activates VTA^DA^ cell bodies, but the mechanism is not understood. *Bottom*: Psychostimulants impair DA reuptake by blocking DAT (cocaine) or reversing the activity of DAT and facilitating DA release (amphetamine), leading to increased dopaminergic tone in the NAc. Alcohol also targets PFC^GLU^ inputs to the NAc, but the net effect on PFC^GLU^ activity is unknown. AC: adenylyl cyclase; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; CB~1~R: cannabinoid 1 receptor; DA: dopamine; DAT: dopamine transporter; D~1~R: dopamine D~1~ receptor; GABA: gamma- aminobutyric acid; GIRK: G protein-coupled inwardly rectifying K^+^ channel; GLU: glutamate; mGluR: metabotropic glutamate receptor; μOR: mu opioid receptor; NAc: nucleus accumbens; nACh: nicotinic acetylcholine receptor; NMDA: *N*-methyl-D-aspartate receptor; PFC: prefrontal cortex; SNARE: soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor; VG Ca^2+^: voltage-gated Ca^2+^ channel; VTA: ventral tegmental area.](fnins-14-00569-g004){#F4}

### Psychostimulants {#S4.SS4.SSS1}

All psychostimulants directly enhance striatal DA release via disruption of dopamine transporter (DAT) activity ([@B273]), though they do so via distinct mechanisms. Cocaine blocks DAT-mediated reuptake of DA, while amphetamine reverses DAT activity and induces DA release from VTA^DA^ terminals ([@B150]; [@B167]). Psychostimulants also acutely increase glutamate transmission in the PFC, NAc, and VTA ([@B283]; [@B376]; [@B304]), indicating broad increases in activity throughout the C-BG-T network following psychostimulant use. The combination of enhanced glutamatergic and dopaminergic input to the NAc facilitates the transition of MSNs to the up- state, and activation of DA-dependent signaling cascades ([@B219]; [@B99]). For example, psychostimulants acutely increase activation of the immediate early gene *Fos* in striatal dMSNs and iMSNs ([@B8]; [@B347]; [@B101]). *Fos* encodes a number of proteins, including ΔFosB, that have been widely implicated in addiction pathology, and enhanced activation in the NAc is thought to contribute to long-term disruptions in normal C-BG-T activity ([@B238]). Co-administration of nicotine, alcohol, or heroin enhances psychostimulant-induced DA release into the NAc ([@B42]; [@B222]; [@B257]), though specific combinations do so via divergent mechanisms. For example, administration of cocaine and nicotine simultaneously activates VTA^DA^ neurons and disrupts DA reuptake ([@B222]; [@B80]), resulting in a greater magnitude of DA release into the NAc than that evoked from either drug alone. Notably, some polydrug combinations that include psychostimulants have divergent and opposing effects on the C-BG-T circuit. Co-administration of alcohol with cocaine induces hepatic production of cocaethylene, which can target DAT and presynaptic D~2~ autoreceptors to amplify DA release ([@B42]). However, alcohol also prevents cocaine-induced glutamate transmission in the NAc core ([@B317]). Lastly, polydrug studies with psychostimulants have identified an exacerbation of drug-induced cellular toxicity compared to psychostimulant use alone. Specifically, co-administration of heroin with cocaine decreases metabolic activity, increases intracellular Ca^2+^ signaling, and decreases mitochondrial membrane potential ([@B71]). Collectively, these effects contribute to enhanced caspase 3-dependent apoptotic activity and subsequent cell death compared to either drug alone ([@B71]).

### Nicotine {#S4.SS4.SSS2}

Unlike psychostimulants, nicotine enhances DA release via activation of nicotinic acetylcholine (nACh) receptors within the VTA. nACh receptors are non-selective cation channels, with permeability to Na^+^, K^+^, and Ca^2+^, and their activation leads to depolarization and enhanced neurotransmitter release ([@B15]). The reinforcing effects of nicotine are primarily due to nicotine's activity on somatodendritic nACh receptors located on VTA^DA^ neurons and on presynaptic nACh receptors located on PFC^GLU^ inputs ([@B244]). Acute nicotine exposure activates both presynaptic PFC inputs ([@B111]; [@B264]) and VTA^DA^ cell bodies ([@B45]; [@B267]), triggering phasic DA release into the NAc ([@B74]; [@B265]). Notably, nicotine-evoked DA release is occluded with blockade of glutamate receptors or activation of GABA~B~ receptors ([@B96]; [@B176]), highlighting the extensive regulation of VTA^DA^ neuron activity by local VTA microcircuitry. Studies have not examined how the acute effects of nicotine are changed by polydrug use.

### Opioids {#S4.SS4.SSS3}

Although opioids are differentiated by their origin, potency, and receptor bias factor ([@B299]), all opioids exert their rewarding effects via activation of mu opioid (μO) receptors. μO receptors are expressed both somatodendritically and axonally ([@B5]), but the primary mechanism of opioid-induced DA release relies on presynaptic inhibition of VTA^GABA^ neurons. μO receptors are inhibitory G protein-coupled receptors (GPCRs), and their activation reduces neuronal excitability via four mechanisms: (1) Gα-mediated inhibition of cAMP-dependent signaling cascades (e.g. PKA, CREB), (2) Gβγ-mediated activation of G protein-coupled inwardly rectifying K^+^ (GIRK) channels, (3) Gβγ-mediated inactivation of voltage-gated Ca^2+^ channels, and (4) Gβγ-mediated inhibition of SNARE-dependent vesicle release ([@B30]; [@B23]; [@B22]; [@B3]; [@B378]). Acute exposure to opioids inhibits VTA^GABA^ neurons ([@B156]; [@B65]), resulting in subsequent disinhibition of VTA^DA^ neurons and phasic DA release into the NAc ([@B138]; [@B273]). Nonetheless, although opioids facilitate DA release into the striatum, whether this DA transmission is necessary for opioid reward remains a point of debate ([@B7]). Opioids activate VTA^DA^ neurons *in vivo* and increase DA in the NAc ([@B85]; [@B156]), but neither lesions of the NAc nor systemic antagonism of DA receptor blockades have an effect on opioid reward ([@B95]; [@B351]; [@B247]; [@B302]). Given the divergent mechanism of action for opioids compared to psychostimulants and nicotine, it is not surprising that co-administration of these drugs augments the acute effects of opioids. Indeed, simultaneous administration of opioids and psychostimulants produces an additive increase in DA release in the NAc, and prolongs elevated levels of DA and its metabolites, DOPAC and HVA ([@B379]). Similarly, simultaneous administration of opioids and nicotine enhances opioid-evoked DA release in the NAc and dorsal striatum ([@B356]). Cross-tolerance to opioid-mediated analgesia has also been shown following pre-exposure to nicotine and cannabis ([@B300]), and chronic nicotine treatment dose-dependently reduces analgesic tolerance to opioids in a nACh receptor-dependent manner ([@B130]; [@B80]). Interestingly, pretreatment with Ca^2+^ channel blockers or naloxone prevents this tolerance, suggesting a complex pharmacological interaction between opioids and nicotine ([@B21]). Notably, cross-tolerance to opioid analgesia is mediated via divergent mechanisms for different polydrug combinations. Nicotine and opioid cross-tolerance is mediated by μO and nACh receptors ([@B130]; [@B80]) while cannabinoid and opioid cross-tolerance is mediated by μO receptors and cannabinoid 1 (CB~1~) receptors ([@B279], [@B278]).

### Cannabinoids {#S4.SS4.SSS4}

Cannabis contains two principal cannabinoids with varying affinity for cannabinoid (CB) receptors: THC is a partial agonist with moderate affinity for both CB~1~ and CB~2~ receptors whereas CBD has extremely low affinity for CB~1~ and CB~2~ receptors and signals through an unknown mechanism ([@B260]). Interestingly, pretreatment with a range of CBD doses has no effect on THC self-administration ([@B362]), indicating non-overlapping signaling pathways for each cannabinoid. CB~1~ receptors are expressed on presynaptic terminals throughout the CNS and are responsible for the psychoactive effects of cannabis, while CB~2~ receptors are primarily expressed on immune cells of the CNS and PNS and are primarily responsible for the antinociceptive and anti-inflammatory effects of cannabis ([@B260]). Both subtypes signal through inhibitory GPCR signaling pathways (similar to opioids), and activation of the receptors results in presynaptic inhibition (via activation of GIRK channels and inhibition of VG Ca^2+^ channels) and downregulation of cAMP-dependent signaling cascades. CB~1~ receptors are heavily expressed on presynaptic terminals of VTA^GABA^ neurons as well as NAc dMSNs that target VTA^DA^ neurons ([@B336]; [@B207]), and activation of CB~1~ receptors reduces GABA-mediated inhibitory postsynaptic currents in VTA slices ([@B54]). CB~1~-mediated disinhibition of VTA^DA^ neurons results in an increase in burst firing ([@B106]; [@B86]) and subsequent release of DA into the NAc ([@B342]; [@B55]; [@B97]), and these effects are blocked by systemic or intra-VTA naloxone ([@B55]; [@B337]). Similar to other drugs, the acute effects of cannabinoids on C-BG-T network activity are broad and engage multiple neurotransmitter systems. For example, acute THC increases both DA and glutamate signaling in the NAc and PFC ([@B268], [@B269]), but decreases GABA signaling in the VTA and PFC ([@B54]; [@B268]). Collectively, these alterations in signaling reduce inhibitory feedback within the C-BG-T and facilitate behavioral output. Alcohol consumption prior to cannabis use enhances plasma THC levels and increases self-reported euphoria in humans ([@B206]), indicating synergistic effects between the two drugs. Moreover, simultaneous administration of cannabinoids with psychostimulants or opioids enhances activation of VTA^DA^ neurons ([@B270]), and simultaneous administration of THC and nicotine increases cFos activation throughout the C-BG-T ([@B348]).

### Alcohol {#S4.SS4.SSS5}

Despite its widespread use, much less is known about the mechanisms underlying the acute effects of alcohol. Alcohol activates dissociated VTA^DA^ neurons ([@B35]) and induces DA release into the NAc ([@B366]; [@B274]; [@B189]), similar to other potentially addictive drugs. However, GABAA receptors are known to play a central role in the effects of alcohol ([@B151]; [@B201]). For example, alcohol potentiates GABA~A~ signaling both in cortical slices and neuronal cultures ([@B1]; [@B286]; [@B287]; [@B338]). Given that NAc dMSNs selectively inhibit VTA^GABA^ neurons via GABA~A~-mediated signaling ([@B91]), it is possible that alcohol facilitates phasic DA release from VTA^DA^ neurons via inactivation of local VTA^GABA^ neurons. In support of this hypothesis, alcohol inhibits VTA^GABA^ neurons ([@B316]), and intra-VTA infusion of GABA~A~ agonists dose-dependently increase DA release ([@B159]). In addition to GABA, the acute effects of alcohol are dependent on glutamatergic signaling within the C-BG-T ([@B125]; [@B183]). Alcohol increases glutamate release in the NAc and VTA via activation of presynaptic D~1~ receptors ([@B242]; [@B373]), suggesting that alcohol engages a feedforward loop for activation of VTA^DA^ neurons. Polydrug use with alcohol produces synergistic effects throughout the C-BG-T, likely as a result of alcohol's unique pharmacological profile. For example, chronic pretreatment with nicotine enhances acute alcohol-induced DA release in the NAc ([@B155]; [@B24]), and elevated levels of DA, DOPAC, and HVA persist for over an hour ([@B341], [@B340]; [@B88]). Additionally, alcohol and nicotine co-administration acutely increase production of BDNF and GDNF in the NAc ([@B344]), along with increases in glutamatergic signaling in the VTA and PFC ([@B83]; [@B94]). Notably, this wide activation of the C-BG-T network is absent following administration of either drug alone, demonstrating a unique mechanism of action for alcohol and nicotine polydrug use.

Mechanisms of Addiction: Long-Term Alterations {#S4.SS5}
----------------------------------------------

Long-term use of psychostimulants, nicotine, opioids, cannabinoids, and alcohol results in widespread and disparate changes throughout the C-BG-T network, yet there are notable alterations that are shared across drugs ([Figure 5](#F5){ref-type="fig"}). These long-term adaptations contribute to transitions from binge/intoxication phases to withdrawal and negative affect, followed by preoccupation and compulsive drug-seeking ([@B175]). For example, acute withdrawal produces a transient reduction in tonic DA levels in the NAc ([@B367]; [@B87], [@B86]; [@B141]). This is followed by a persistent increase in excitability of VTA^DA^ neurons ([@B210]; [@B25]; [@B69]; [@B186]; [@B375]), which contributes to enhanced cue-evoked phasic DA release during abstinence ([@B359]). Conversely, withdrawal also produces a persistent reduction in long-term depression (LTD) and intrinsic excitability in NAc MSNs, as well as a reduction in striatal D~2~ receptor binding ([@B343]). As described earlier, striatal D~2~ receptors are primarily expressed on iMSNs, can serve as a "stop" signal on the C-BG-T circuit, and reduced D~2~ availability has been ubiquitously linked to a range of addictive diseases, including drug addiction and obesity ([@B358]; [@B179]; [@B108]). Finally, these drugs all drive a persistent increase in ΔFosB expression in cortical pyramidal cells and NAc dMSNs ([@B202]), which has been linked to drug-seeking during abstinence ([@B238]). Importantly, although chronic use of any of these drugs results in a multitude of other transient and/or persistent changes across the C-BG-T network, it is beyond the scope of the current review to provide an exhaustive summary. Rather, the focus will be on changes in plasticity, morphology, and connectivity within the VTA, NAc, and PFC following both single and polydrug use, with an emphasis on how the antagonistic and synergistic effects of these drugs can differentially disrupt C-BG-T network dynamics.

![Persistent disruptions in synaptic and structural plasticity caused by long-term use of potentially addictive drugs. Studies are organized by cell type (columns) and type of disruption (rows), with symbols depicting the net change in plasticity and color depicting which drug was tested. Data from [@B28], [@B162], [@B163], [@B289], [@B290], [@B8], [@B210], [@B73], [@B347], [@B38], [@B288], [@B295], [@B4], [@B131], [@B236], [@B172], [@B173], [@B144], [@B380], [@B350], [@B160], [@B243], [@B294], [@B31], [@B313], [@B194], [@B72], [@B181], [@B202], [@B343], [@B222], [@B261], [@B25], [@B69], [@B92], [@B134], [@B232], [@B109]), [@B186], [@B91], [@B312], [@B375], [@B149], [@B182], [@B218], [@B239], [@B266], and [@B275].](fnins-14-00569-g005){#F5}

### Psychostimulants {#S4.SS5.SSS1}

Psychostimulants produce long-term disruptions in glutamate homeostasis and alterations in neuronal morphology throughout the C-BG-T network ([@B158]; [@B7]). Repeated cocaine administration weakens GABA~A~-mediated inhibition of prelimbic (PrL) pyramidal neurons, increasing their excitability and augmenting excitatory drive to the NAc ([@B236]; [@B144]). Similarly, chronic cocaine increases glutamatergic input to the VTA ([@B295]; [@B31]) and weakens GABA~B~-mediated inhibition of VTA^DA^ neurons ([@B28]; [@B91]), leading to a facilitation of VTA^DA^ neuron activity. Additionally, psychostimulants generate silent synapses on dMSNs via synaptogenesis ([@B29]; [@B127]) and depress glutamate release from PrL inputs to the NAc core ([@B11]), weakening striatal output. Importantly, cocaine-silenced synapses on dMSNs can be unsilenced during withdrawal via recruitment of AMPA receptors ([@B29]; [@B127]), and a low dose psychostimulant challenge restores glutamate release into the NAc core ([@B29]; [@B11]), suggesting the promotion of allostasis. Finally, repeated psychostimulant exposure increases expression of ΔFosB in PFC pyramidal neurons and NAc dMSNs ([@B259]), which contributes to an increase in dendritic branching that persists for at least 30 days of abstinence ([@B289], [@B290]; [@B294]). Studies have not examined how these effects of psychostimulants are changed by polydrug use.

### Nicotine {#S4.SS5.SSS2}

Similar to psychostimulants, long-term nicotine administration reduces GABA~B~-mediated signaling in the mPFC and NAc ([@B4]), dampening inhibitory drive onto the C- BG-T network. Additionally, nicotine enhances glutamatergic input to VTA^DA^ neurons ([@B210]; [@B295]), and sensitizes evoked DA release into the NAc ([@B17]). Repeated nicotine use also leads to an upregulation of nicotinic acetylcholine receptors throughout the C-BG-T, including the PFC and midbrain ([@B212]; [@B16]; [@B33]). Conversely, chronic nicotine exposure weakens both glutamatergic and GABAergic inputs to the NAc during abstinence, potentially via enhanced sensitivity of NAc D~2~ receptors ([@B232]). Because NAc output is heavily regulated via local GABAergic microcircuitry, increased activity of iMSNs would likely dampen overall NAc output. This is supported by the upregulation of Ca^2+^-permeable AMPA receptors in the NAc that are capable of conducting Ca^2+^ in the absence of NMDA receptor activation ([@B275]). Long-term nicotine use also produces a persistent increase in mPFC pyramidal cell and NAc MSN dendritic branching ([@B38]; [@B131]; [@B92]), similar to psychostimulants. Moreover, adolescent nicotine use enhances synaptic pruning, microglial activation, and inflammatory cytokine expression throughout the C-BG-T via a D~2~ receptor-mediated mechanism ([@B198]). Repeated co-administration of psychostimulants and nicotine augments long-term potentiation (LTP) induction and ΔFosB in the NAc core ([@B194]; [@B222]). Interestingly, these effects are absent following sequential administration of these drugs ([@B194]), indicating a unique pharmacological profile for concurrent nicotine and psychostimulant administration.

### Opioids {#S4.SS5.SSS3}

Similar to psychostimulants and nicotine, long-term exposure to opioids strengthens glutamatergic input to VTA^DA^ neurons ([@B28]; [@B295]). They also weaken GABAergic inhibition of VTA^DA^ neurons ([@B210]; [@B243]; [@B72]) via a reduction of dMSN-mediated GABA~B~ inhibition ([@B28]). This effect is largely driven by MSNs in the NAc ([@B374]), indicating a persistent disruption in NAc output. Unlike psychostimulants and nicotine, however, long-term exposure to opioids decreases dendritic branching and spine density in NAc MSNs and mPFC pyramidal cells ([@B8]; [@B288]; [@B350]). Within the NAc, long-term opioid exposure weakens glutamatergic input to NAc shell iMSNs ([@B134]; [@B218]) and induces silent synapses on iMSNs via AMPA internalization ([@B127]). Moreover, during withdrawal, opioid-generated silent synapses on iMSNs are eliminated ([@B127]), and the intrinsic excitability of iMSNs is weakened ([@B218]). Given that MSNs create a dense network of lateral inhibition within the NAc, with ∼30% of iMSNs synapsing onto other iMSNs or dMSNs ([@B339]), it is possible that opioid-induced disruptions in iMSN signaling could disrupt local NAc microcircuitry and facilitate aberrant C-BG-T network dynamics. Studies have not examined how these effects of opioids are changed by polydrug use.

### Cannabinoids {#S4.SS5.SSS4}

Repeated THC administration weakens glutamatergic signaling from the mPFC to the NAc ([@B312]; [@B149]; [@B239]) but strengthens input from the basolateral amygdala and ventral hippocampus to the NAc shell ([@B149]), suggesting a rewiring of excitatory input to the NAc following long-term cannabinoid exposure. Notably, repeated THC administration also occludes CB~1~-mediated LTD on VTA^GABA^ neurons ([@B109]), indicating a loss of local inhibitory drive on VTA^DA^ neurons. Additionally, adolescent THC administration followed by abstinence reduces intrinsic excitability of PrL neurons ([@B266]) and weakens glutamatergic input to the VTA ([@B182]), indicating the presence of a hypoglutamatergic state induced by cannabinoids. THC exposure also produces long-lasting changes in morphology throughout the C-BG-T, increasing dendritic spine length and branching in the mPFC and NAc shell ([@B172]) and dendritic spine density in the NAc shell ([@B173]), but reducing the size of VTA^DA^ neurons ([@B313]; [@B14]). Repeated co-administration of THC and nicotine enhances expression of ΔFosB in the NAc, and acute withdrawal dysregulates glutamatergic input to the NAc and PFC ([@B275]).

### Alcohol {#S4.SS5.SSS5}

Similar to opioids, extended alcohol exposure decreases dendritic branching and spine density in the NAc shell and mPFC ([@B380]; [@B261]), and withdrawal from alcohol reduces tonic DA levels in the NAc ([@B291]; [@B87]). However, alcohol withdrawal also causes distinct changes throughout the C-BG-T network, including reduced GABAergic signaling in the NAc and hippocampus ([@B162], [@B163]; [@B73]) and increased glutamatergic signaling in the NAc and PFC ([@B73]; [@B181]). Notably, this increased glutamatergic signaling is due to disrupted glutamate reuptake, rather than enhanced glutamate release ([@B256]). *In vitro* polydrug exposure to alcohol and nicotine induces a 2.5-fold increase in caspase-3 activation, elevating apoptotic cascades and driving cell death ([@B281]). Interestingly, however, alcohol or nicotine withdrawal-induced neurodegeneration is less severe following co-administration of both drugs ([@B246]), indicating a unique molecular pathology following nicotine and alcohol polydrug use.

Conclusion {#S5}
==========

Improving the translatability and mapping of behavioral measures in preclinical models to accurately reflect polysubstance history and dependency in clinical populations is essential. This is particularly true, as human imaging studies are limited by an inability to control for intake history, making behavioral models in other species advantageous for assessing polydrug history under controlled intake conditions. However, these models are limited in their capacity to fully encompass the complex social and environmental contexts that contribute to the unique use patterns for multiple substances with addiction potential. Nevertheless, when designing experiments in clinical or preclinical populations, factors such as time of day of intake, temporal proximity of intake, and environmental preferences for administration must be consideredfor each substance class. For instance, cocaine use is predominantly favored outside of home environments, whereas heroin use is greater in "home" contexts in both humans and rodents ([@B48]; [@B9]; [@B81]; [@B79]). In addition, route of drug administration (e.g. oral ingestion, injection, and inhalation) is especially important to factor into studies, as it leads to unique patterns of polysubstance history that may impact the developmentand severity of addiction behaviors ([@B292]).

Accounting for temporal patterns of drug use is also essential. Although many studies have focused on simultaneous drug combinations, sequential patterns of polydrug consumption are more frequently reported ([@B193]; [@B292]) and produce unique circuit adaptations following acute and repeated drug exposure ([@B71]). Understanding sex differences in frequency and pattern of polydrug use ([@B217]), drug discrimination ([@B311]), and circuit alterations ([@B47]; [@B211]) is also necessary to fully understand the interactions and impacts of polydrug use in clinical populations. Furthermore, although powerful behavioral economic models allow comparisons across drug classes, these experiments must be designed with consideration of different scales of intake and indifference points for drug valuation in order to accurately model parameters and interpret data ([@B240]). As these factors, coupled with the interplay of socioeconomic background, social environment, and access strategies, affect frequency and susceptibility to polydrug use ([@B119]; [@B139]), encompassing these influences in preclinical models is crucial for translational relevance of findings.

It is important to appreciate that novel preclinical paradigms are continuously being developed to model different routes of drug administration and to study relapse under clinically relevant conditions. For instance, recently established models allow for voluntary control over self-administration of vaporized ethanol ([@B77]; [@B171]), cannabis ([@B220]; [@B105]), and nicotine ([@B213]). In addition, multiple models for inducing drug abstinence are being introduced. For instance, voluntary abstinence is achieved via pairing of drug-taking with adverse consequences such as shock-lever pairings or electrified barriers placed in front of levers ([@B177]; [@B353]), andthrough choice procedures involving a drug versus an alternative reinforcer (e.g. palatable food or social interaction) ([@B353], [@B355], [@B354]). These paradigms are notable for their high translational value and may be powerful for understanding the neural basis of therapies such as contingency management, in which abstinence from drug use results in a monetary reward. Combining these models with behavioral economic paradigms could clarify how the relative value of drugs and alternative reinforcers changes with polydrug use to improve treatment efficacy. Addiction is a complex disease with multiple, highly variable factors contributing to the initiation and maintenance of drug use, as well as relapse. Given the widespread prevalence of polydrug use among drug users, it is critical that we incorporate this variablility into human studies and animal models. This will help to determine if polysubstance use exacerbates SUD severity, if increased SUD severity drives polysubstance use, or if there is a bidirectional relationship between the two. Though challenging, understanding the behavioral, genetic, and environmental contributions to polysubstance use and addiction, as well as the mechanisms that underlie addiction-severity and relapse, will aid in developing efficacious treatment and policy strategies to combat this ongoing public health crisis.
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